Thursday, January 29, 2009
Can you decide during the PACES MRCP exam whether the R eye is having exopthalmos or the L eye is having ptosis ?
Do you need to toss the coin to decide this in the exam.....50% right, 50% wrong.
If you see the neck you may see a goitre but again...don't be fooled as Graves disease may coexist with myasthenia gravis as both of them are autoimmune disease
One technique to know fast is think logically -
If you see this patient in Station 3(Neuro) - the possibility of L ptosis is higher
If you see this patinet in Station 5(Endocrine) - the possibility of R exopthalmos is higher
So, in Station 3, you would check the eyes as if it was approach to ptosis and if in Station 5 you would check the eyes and look for signs of thyrotoxicosis.
This patient actually has Graves disease.
Tuesday, January 27, 2009
You will hear this term over and over again from medical school to MRCP PArt 1 to MRCP PArt 2a to PACES(most of the time in history station for differential of headache or transient blurring of vision).
Mean age of diagnosis 70 years old
Slightly more common in women
Headache - usually localised
Jaw claudication (pain on chewing)
Proximal muscle stiffness and pain
Visual loss (Amaurosis fugax)
Tender and thickened scalp veins
Optic disc swollen and later pale (AION)
ESR elevated (one of the differential for ESR >100)
Superficial temporal artery biopsy - intimal thickening and medial damage, giant cells with inflammatory cell infiltration in the internal elastic lamina (GOLD STANDARD)
A general treatment regime for GCA patients that many physicians follow begins with a 70mg/day prednisone dose.
After the first week, the dose is reduced by 10mg every week until the dosage reaches 20mg/day (Schmidt, 2006).
However, some physicians recommend that the high initial dose be maintained for two weeks (Rahman & Rahman, 2005).
Once the 20mg/day level is reached, the dosage is lowered by 2.5mg per week.
Then, when the dosage reaches 10mg/day, it is reduced by 1mg every month depending on the symptoms and test results (Schmidt, 2006).
Most patients remain on corticosteroids for 1-2 years, although some may require long-term steroid treatment (Schmidt, 2006; Piptone et al., 2005).
The reason that treatment of GCA is usually short in duration is because GCA is a self-limiting disease for most patients (although the mechanism for this limitation is unknown) (Azhar et al., 2005; Schmidt, 2006).
Longer corticosteroid treatment is typically required for patients with more severe GCA; these patients usually have cytokine levels (such as TNF-α) above most GCA patients (Hernandez-Rodriguez et al., 2004).